Stockscreener 앱 받기
11.08
1.20%
-0.135
시간 외 거래:
11.10
0.02
+0.18%
전일 마감가:
$11.21
열려 있는:
$11.3
하루 거래량:
695.95K
Relative Volume:
0.70
시가총액:
$946.42M
수익:
-
순이익/손실:
$-43.16M
주가수익비율:
-20.15
EPS:
-0.55
순현금흐름:
$-29.31M
1주 성능:
-1.07%
1개월 성능:
+8.73%
6개월 성능:
+30.20%
1년 성능:
+66.87%
1일 변동 폭
$10.90
$11.40
1주일 범위
$10.52
$11.65
52주 변동 폭
$4.9301
$14.44
Anavex Life Sciences Corporation Stock (AVXL) Company Profile
명칭
Anavex Life Sciences Corporation
전화
844-689-3939
주소
630 5TH AVENUE, NEW YORK
AVXL을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AVXL
Anavex Life Sciences Corporation
|
11.08 | 937.02M | 0 | -43.16M | -29.31M | -0.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
366.54 | 98.88B | 11.42B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.00 | 58.84B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
438.93 | 56.12B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
661.83 | 41.20B | 3.05B | 1.28B | -614.78M | 19.58 |
|
ONC
Beone Medicines Ltd Adr
|
288.18 | 35.49B | 3.81B | -644.79M | -669.77M | -6.24 |
Anavex Life Sciences Corporation Stock (AVXL) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2022-12-06 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2022-06-23 | 개시 | Berenberg | Buy |
| 2021-09-23 | 개시 | BTIG Research | Buy |
| 2020-12-16 | 재확인 | H.C. Wainwright | Buy |
| 2020-09-28 | 개시 | Ladenburg Thalmann | Buy |
| 2020-02-27 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-06-18 | 개시 | Janney | Buy |
| 2018-05-16 | 재개 | Maxim Group | Buy |
| 2018-03-08 | 개시 | ROTH Capital | Buy |
| 2018-02-13 | 재확인 | Maxim Group | Buy |
| 2017-09-29 | 재개 | Noble Financial | Buy |
| 2017-02-07 | 개시 | Noble Financial | Buy |
| 2016-03-29 | 개시 | FBR Capital | Outperform |
모두보기
Anavex Life Sciences Corporation 주식(AVXL)의 최신 뉴스
Sector ETF performance correlation with Anavex Life Sciences Corp.Stock Entry Points Based on Technicals - Newser
Historical volatility pattern of Anavex Life Sciences Corp. visualizedEquity Portfolio Outlook and Performance Summary - Newser
What technical models suggest about Anavex Life Sciences Corp.’s comebackPrice Movement and Market Sentiment Analysis - Newser
Published on: 2025-08-10 02:07:10 - Newser
Can a trend reversal in Anavex Life Sciences Corp. lead to recoveryYearly Trend Summary and Opportunity Breakdown - Newser
Can Anavex Life Sciences Corp. recover in the next quarterROI Focused Setup Screener With Exit Markers - Newser
How Resilient Is Anavex Life Sciences Corp. Stock During Economic DownturnsFree Risk Controlled Short Term Trade Plans - Newser
Is Anavex Life Sciences Corp. stock reversal real or fakeIntraday Price Forecast Using Volume Models - Newser
Will Anavex Life Sciences Corp. outperform the marketVolume Spike Detection for Early Breakouts - Newser
Risk adjusted return profile for Anavex Life Sciences Corp. analyzedChart Signal and Short-Term Forecast Tracker - Newser
Envestnet Asset Management Inc. Sells 6,064 Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Real time social sentiment graph for Anavex Life Sciences Corp.Real Market Tracker with Price Action Tools - Newser
How high can Anavex Life Sciences Corp. stock goAI Entry Timing Prediction for Swing Traders - Newser
D. Boral Capital Reiterates Buy Rating for Anavex Life Sciences (NASDAQ:AVXL) - Defense World
Understanding Anavex Life Sciences Corp.’s price movementConservative Investment Setup and Risk Analysis - Newser
Identifying reversal signals in Anavex Life Sciences Corp.Trend Following Ideas with Volume Confirmation - Newser
Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Finan - GuruFocus
Anavex Life Sciences Corp. Schedules Third Quarter Financial Results and Conference Call for August 12, 2025 - Quiver Quantitative
Anavex Life Sciences Earnings: Latest Updates on Alzheimer's and Parkinson's Drug Development Coming August 12 - Stock Titan
Anavex Life Sciences to Announce Fiscal 2025 Third Quarter Financial Results on Tuesday, August 12, 2025 - The Manila Times
Alzheimer's Disease Disease-Modifying Therapies Markets, 2023-2025 & 2026-2030 | Key Marketed Products, Clinical Trials, Competitive Scenario and R&D Activities - GlobeNewswire Inc.
What data driven models say about Anavex Life Sciences Corp.’s futureFree Stock Market Watch With Alerts - Newser
Can Anavex Life Sciences Corp. rally from current levelsHigh Confidence Strategy with Trend Alignment - Newser
Is Anavex Life Sciences Corp. stock a growth or value playDay Trading Setup Forecast with Trend Model - Newser
What catalysts could drive Anavex Life Sciences Corp. stock higher in 2025Maximize your gains with expert trading tips - Jammu Links News
What institutional investors are buying Anavex Life Sciences Corp. stockGet real-time alerts on top-performing stocks - Jammu Links News
Should I hold or sell Anavex Life Sciences Corp. stock in 2025Get timely alerts on market movers - Jammu Links News
Is it the right time to buy Anavex Life Sciences Corp. stockMassive stock growth - Jammu Links News
What are analysts’ price targets for Anavex Life Sciences Corp. in the next 12 monthsOutstanding investment returns - Jammu Links News
What are Anavex Life Sciences Corp. company’s key revenue driversFinancial News Entry Points Backed By Experts - Jammu Links News
How volatile is Anavex Life Sciences Corp. stock compared to the marketChart Pattern Planner With Low Risk - jammulinksnews.com
KLP Kapitalforvaltning AS Acquires Shares of 16,400 Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Choreo LLC Makes New $194,000 Investment in Anavex Life Sciences Corp. (NASDAQ:AVXL) - Defense World
Anavex Life Sciences Corporation (AVXL) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.24%
3.39%
자본화:
|
볼륨(24시간):